What is Precision BioScience?
Precision BioSciences operates at the intersection of advanced biotechnology and genetic engineering. By leveraging a proprietary genome editing method, the company is actively developing novel therapeutics designed to overcome cancer and address various genetic disorders. Beyond human health, the firm applies its technological expertise to enhance the productivity and safety of global food sources, positioning itself as a versatile player in the life sciences market.
The company's market position is bolstered by a deep commitment to scientific rigor and strategic partnerships. By focusing on high-impact areas where unmet medical needs remain prevalent, Precision BioSciences has attracted a sophisticated syndicate of institutional investors and industry partners who provide both financial resources and operational guidance.
How much funding has Precision BioScience raised?
Precision BioScience has raised a total of $321M across 4 funding rounds:
Series A
$25.6M
Series B
$110M
Debt
$40M
Stock Offering
$145.4M
Series A (2015): $25.6M with participation from Osage University Partners, F-Prime Capital Partners, Amgen Business Development, Baxter International, Longevity Fund companies, and venBio
Series B (2018): $110M led by RA Capital Management, Leerink Partners, Longevity Fund companies, Brace Pharma Capital, Cowen Healthcare Investments, Agent Capital, Pontifax AgTech, Osage University Partners, Franklin Templeton Investments, F-Prime, Alexandria Venture Investments, venBio, ArrowMark Partners, Vivo Capital, Gilead Sciences, Cormorant Asset Management, OCV Partners, DUMAC, Adage Capital Management, Amgen Business Development, and Ridgeback Capital
Debt (2019): $40M supported by Undisclosed
Stock Issuance/Offering (2019): $145.4M featuring Undisclosed
Key Investors in Precision BioScience
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies.
venBio
venBio is a life sciences investment firm that partners with industry leaders to develop innovative medicines and technologies, focusing on novel therapeutics for unmet medical needs.
Longevity Fund companies
The Longevity Fund is a venture capital firm focused on funding companies that develop drugs for age-related diseases and longevity.
What's next for Precision BioScience?
Looking ahead, the strategic focus for Precision BioSciences remains the clinical validation of its genome editing candidates. With the support of its recent capital infusion, the company is well-positioned to navigate the complexities of late-stage development and regulatory approval processes. The firm is expected to prioritize the expansion of its therapeutic portfolio while continuing to refine its proprietary technology to maintain a competitive edge in the rapidly evolving biotech landscape.
Furthermore, the company will likely leverage its existing network of strategic partners to explore new commercialization pathways. As it matures, the focus will shift toward sustainable growth and the long-term integration of its innovations into mainstream medical and agricultural practices, ensuring that its scientific advancements translate into tangible patient and consumer benefits.
